[1]马小娜,张 辉,王宏东,等.银屑病患者血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)与疾病严重程度的关联性研究[J].现代检验医学杂志,2017,32(02):41-44.[doi:10.3969/j.issn.1671-7414.2017.02.011]
　MA Xiao-na,ZHANG Hui,WANG Hong-dong,et al.Correlation between Plasma-soluble Urokinase Plasminogen Activator Receptor(suPAR)Levels and Disease Severity in Psoriasis Patients[J].Journal of Modern Laboratory Medicine,2017,32(02):41-44.[doi:10.3969/j.issn.1671-7414.2017.02.011]
点击复制

银屑病患者血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)与疾病严重程度的关联性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年02期
页码:
41-44
栏目:
论著
出版日期:
2017-03-25

文章信息/Info

Title:
Correlation between Plasma-soluble Urokinase Plasminogen Activator Receptor(suPAR)Levels and Disease Severity in Psoriasis Patients
文章编号:
1671-7414(2017)02-041-04
作者:
马小娜1; 张 辉1; 王宏东1; 韩晓虹1; 史龙泉1; 穆 欣2
1.延安大学附属医院皮肤科,陕西延安 716000;
2.西安交通大学第一附属医院皮肤科,西安 710061
Author(s):
MA Xiao-na1; ZHANG Hui1; WANG Hong-dong1; HAN Xiao-hong1; SHI Long-quan1; MU Xin2
1.Department of Dermatology,Affiliated Hospital of Yan'anUniversity, Shaanxi Yan'an 716000,China;
2.Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China
关键词:
银屑病; 可溶性尿激酶型纤溶酶原激活物受体; PASI评分
分类号:
R758.63; R392.11
DOI:
10.3969/j.issn.1671-7414.2017.02.011
文献标志码:
A
摘要:
目的 探索银屑病患者血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平与其疾病严重程度的关联性。方法 选取2013年1月～2015年12月医院就诊的60例银屑病患者(患者组)和60例健康体检者(对照组)。酶联免疫吸附法(ELISA)测定患者组和对照组血浆suPAR水平,Kruskal-Wallis和Mann-Whitney U检验比较血浆suPAR差异。Spearmans's rho分析临床参数与血浆suPAR的相关性。结果 患者组血浆suPAR(3.92±1.04 ng/ml)显著高于对照组(3.03±0.58 ng/ml,Z=13.05,P=0.009)。轻度患者(PASI<10)血浆suPAR(2.67±0.63 ng/ml)显著低于中度(10≤PASI≤20,3.90±1.67 ng/ml,Z=8.00,P=0.035)和重度患者(PASI>20,4.55±1.88 ng/ml,Z=48.5,P=0.031)。患者血浆suPAR与PASI呈正相关(r=0.264,P=0.041)。病程>10年患者(n=35)血浆suPAR(4.43±1.98 ng/ml)显著高于病程<10年患者(n=25,3.41± 0.69 ng/ml,Z=-2.064,P=0.035)。结论 血浆suPAR与银屑病疾病严重程度呈正相关,suPAR可作为银屑病严重程度及疗效评估的指标之一,辅助临床诊断。
Abstract:
Objective To investigate the correlation between plasma-soluble urokinase plasminogen activator receptor(suPAR)levels and disease severity in psoriasis patients.Method 60 psoriasispatients and 60 healthy controls were enrolled from Jan.2013 to Dec.2015 in the hospital.The plasma suPAR of all objects were measured by ELISA.Kruskal-Wallis and Mann-Whitney U test were used to compared plasma suPAR in the difference groups.Correlation between clinical data and plasma suPAR were analyzed by Spearmans's rho method.Result The plasma suPAR of psoriasis patients(3.92±1.74 ng/ml)were higher than controls(3.03±1.08 ng/ml,Z=13.05,P=0.009).The plasma suPAR of mild patients(PASI<10)were lower than moderate patients(10≤PASI≤20, 3.90±1.67 ng/ml,Z=8.00,P=0.035)and severity patients(PASI>20,4.55±1.88 ng/ml,Z=48.5,P=0.031).Positive correlation were found between plasma suPAR and psoriasis area and severity dndex(PASI)score(r=0.264,P=0.041).The plasma suPAR of the patients with disease duration>10 years(n=35,4.43±1.98 ng/ml)were higherthan the patients with disease duration<10 years(n=25,3.41±0.69 ng/ml,Z=-2.064,P=0.035).Conclusion There was a positive correlation between the plasma suPAR and psoriasis disease severity.The Plasma suPAR can be the biomarker of psoriasis disease severity.It facilitate theclinical diagnosis of psoriasis.

参考文献/References:

[1] Zhao Y,Lai W.Patient considerations and targeted therapies in the management of psoriasis in Chinese patients:role of ustekinumab[J].Patient Prefer Adher,2014(8):865-872.
[2] 李 源,李 影,周 芳,等.部分炎症因子在银屑病与胰岛素抵抗相关性中的作用[J].皮肤性病诊疗学杂志,2014,21(3):264-266. Li Y,Li Y,Zhou F,et al.The role of some inflammatory factors inthe relativity of psoriasis and insulin resistance[J].J Diagn Ther Demato-Venereol,2014,21(3):264-266.
[3] Ciccarelli F,De Martinis M,Sirufo MM,et al.Psoriasis induced anti-tumor necrosis factor alpha agents:a comprehensive review of the literature[J].Acta Dermatovenerol Croat,2016,24(3):169-174.
[4] 翟 成,陈 敬,刘毅钧,等.银屑病患者皮损组织中分泌型磷脂酶A2-IIA表达的研究[J].现代检验医学杂志,2015,30(3):113-114. Zhai C,Chen J,Liu YJ,et al.Study on the expression of secretoryphospholipase A2-IIA in lesional skin of patients with psoriasis[J].J Mod Lab Med,2015,30(3):113-114.
[5] 汤雯剑,罗 浩,赵金涛.银屑病患者血清中IL-10与IL-21水平监测的临床应用[J].现代检验医学杂志,2015,30(2):65-67. Tang WJ,Luo H,Zhao JT.Clinical application of IL-10 and IL-21 levels monitoring in patients with psoriasis[J].J Mod Lab Med,2015,30(2):65-67.
[6] Eugen-Olsen J,Giamarellos-Bourboulis EJ.SuPAR:The unspecific markerfor disease presence,severity and prognosi[J].Int J Antimicrob Agents,2015,46(suppl 1):S11-S34.
[7] Backes Y,Vander Sluijs KF,Mackie DP,et al.Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection:a systematic review[J].Intensive Care Med,2012,38(9):1418-1428.
[8] 赵 辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2009:1008-1025. Zhao B.Chinese Journal of Clinical Dermatology[M].Nanjing:Jiangsu Science and Technology Press,2009:1008-1025.
[9] Marks R,Barton SP,Shuttleworth D,et al.Assessment of disease progressin psoriasis[J].Arch Dermatol,1989,125(2):235-240.
[10] Cao LY,Chung JS,Teshima T,et al.Myeloid-derived suppressorcells in psoriasis are an expanded population exhibiting diverse T-cell-supressor mechanisms[J].J Invest Dermatol,2016,136(9):1801-1810.
[11] 李 影,王柳苑,李 源,等.银屑病患者合并代谢性疾病调查分析及其胰岛素抵抗状态评估[J].皮肤性病诊疗学杂志,2013,20(5):318-320. Li Y,Wang LY,Li Y,et al.The survey of prevalence of metabolic diseasesand the assessment of insulin resistance in psoriasis patients[J].J Diagn Ther Demato-Venereol,2013,20(5):318-320.
[12] 王彦军,贾 方,孙建辉.可溶性尿激酶型纤溶酶原激活物受体与心血管疾病的关系[J].国际心血管病杂志,2015,42(2):68-70. Wang YJ,Jia F,Sun JH.Relationship between soluble urokinase plasminogenactivator receptor and cardiovascular diseases[J].Int J Cardovasc Dis,2015,42(2):68-70.
[13] Plewes K,Royakkers AA,Hanson J,et al.Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria[J].Malar J,2014(13):91.
[14] 杨旭伟,张 旸,郑祥雄,等.SLE患者血清suPAR水平与疾病活动度的相关性分析[J].免疫学杂志,2015,31(7):608-611. Yang XW,Zhang Y,Zheng XX,et al.Correlation analysis between soluble urokinase plasminogen activator receptor levels and the severity of disease activation in patients with systemic lupus erythematosus[J].Immuno J,2015,31(7):608-611.
[15] 胡 煜,向 志,栾 超,等.红皮病性银屑病患者WBC升高的临床意义[J].临床皮肤科杂志,2016,45(11):759-761. Hu Y,Xiang Z,Luan C,et al.Clinical significance of leukocytosis in patients with erythrodermic psoriasis[J].J Clin Dematol,2016,45(11):759-761.

相似文献/References:

[1]汤雯剑,罗 浩a,赵金涛b.银屑病患者血清中IL-10与IL-21水平监测的临床应用[J].现代检验医学杂志,2015,30(02):65.[doi:10.3969/j.issn.1671-7414.2015.02.020]
　TANG Wen-jian,LUO Haoa,ZHAO Jin-taob.Clinical Application of IL-10 and IL-21 Levels Monitoring in Patients with Psoriasis[J].Journal of Modern Laboratory Medicine,2015,30(02):65.[doi:10.3969/j.issn.1671-7414.2015.02.020]
[2]梁 彦,张沛欣,冯苗苗.青少年肥胖患者血清可溶性尿激酶型纤溶酶原激活物受体检测的临床意义[J].现代检验医学杂志,2019,34(02):68.[doi:10.3969/j.issn.1671-7414.2019.02.018]
　LIANG Yan,ZHANG Pei-xin,FENG Miao-miao.Study on Detection of Serum Soluble Urokinase Activator Receptorin Obese Adolescents[J].Journal of Modern Laboratory Medicine,2019,34(02):68.[doi:10.3969/j.issn.1671-7414.2019.02.018]

备注/Memo

备注/Memo:
基金项目:陕西省科技攻关项目,项目编号2014K11-02-03-13。
作者简介:马小娜(1975-),女,硕士研究生,副主任医师,研究方向:从事皮肤性病学的临床医疗、教学工作,Tel:13991772860,E-mail:maxiaona197503@163.com。
通讯作者:穆 欣,硕士,主治医师,E-mail:muxin0510@163.com。
更新日期/Last Update: 2017-04-10